Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 184

Sort by

Sort Order Select

Journal Articles

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Blood blood.2024025834.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 596.

https://doi.org/10.1182/blood-2023-181788

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Marlise R. Luskin, Shai Shimony, Julia Keating, Wendy Stock, Hanno Hock, Jacqueline S. Garcia, Maximilian Stahl, Ilene Galinksy, Rebecca Leonard, Howard Weiner, Yael Flamand, Donna S. Neuberg, Richard M Stone, Anthony G. Letai, Eric S. Winer, Marina Y. Konopleva, Nitin Jain, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2023-174269

Published: 2023

Journal Articles

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2023) 142 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2023-181031

Published: 2023

Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2023-178115

Published: 2023

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2023-179168

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Journal Articles

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Marina Y. Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, Abhishek Maiti, Krishna Gundabolu, Kyle Jensen, Jolie Schafer, Gu Mi, Agata Drewniak, Heidi Krenz, Rao Saleem, Giovanni Abbadessa, Naval Daver

Blood (2023) 142 (Supplement 1): 5972.

https://doi.org/10.1182/blood-2023-174030

Published: 2023

Journal Articles

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Josette M Kamel, Mendel Goldfinger, Jiani Chai, Jui Choudhuri, Marina Y. Konopleva, Eric J Feldman, Ioannis Mantzaris, Dennis L Cooper, Aditi Shastri, Nishi Shah, Noah Kornblum, Kira Gritsman, Alejandro Sica, Yanhua Wang, Xuejun Tian, Amit Verma, Swati Goel

Blood (2023) 142 (Supplement 1): 6050.

https://doi.org/10.1182/blood-2023-188243

Published: 2023

Journal Articles

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abhishek Maiti, Satoshi Yamashita, Abdullah Khasawneh, Faith Jessica Paran, Kala Hayes, Gautam Borthakur, Joe R Harman, Shinya Kimura, Courtney D. DiNardo, Thomas A Milne, Michael Andreeff, Yoko Tabe, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2023-178554

Published: 2023

Journal Articles

Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b In Vivo

Valerio Ciaurro, Marina Y. Konopleva, Naval Daver, Anna Skwarska, Maria Paola Martelli

Blood (2023) 142 (Supplement 1): 4169.

https://doi.org/10.1182/blood-2023-182026

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, Annemarie Munoz, Aradhika Dhawan, Nicole Chambers, Karen Fehn, Joel Victor, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Amit Verma, Mimi Kim, Ulrich Steidl, Eric J Feldman, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2023-188176

Published: 2023

Journal Articles

Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML

Zhihong Zeng, Annelies Roobrouck, Geert Deschamps, Helene Bonnevaux, Stephane Guerif, Veronique De Brabandere, Amara Céline, Eline Jonckheere, Angela Virone-Oddos, Marielle Chiron, Melissa Dullaers, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2023-186012

Published: 2023

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Blood (2023) 142 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2023-186514

Published: 2023

Journal Articles

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Kateryna Fedorov, Alexander Sisto, Josette Kamel, Mark Forsberg, Kith Pradhan, Nishi Shah, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Kira Gritsman, Amit K. Verma, Eric J Feldman, Marina Y. Konopleva, Ioannis Mantzaris

Blood (2023) 142 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2023-180856

Published: 2023

NARROW

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b In Vivo

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only